Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2020-12-11 AGM Information
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Kallelse till extra bolagsstämma i Medivir AB (publ)
AGM Information Classification · 98% confidence The document is titled "Kallelse till extra bolagsstämma i Medivir AB (publ)" which translates to 'Notice of Extraordinary General Meeting in Medivir AB (publ)'. It details the procedures for voting (via advance voting due to Covid-19), the proposed agenda items (including capital reduction and rights issue), and shareholder rights. This content is characteristic of a formal notice calling for a shareholder meeting and outlining the proposals to be voted upon, which aligns perfectly with the definition of materials shared during a General Meeting, specifically an Extraordinary General Meeting (EGM). The closest matching category is AGM-R (AGM Information), as it covers materials related to general shareholder meetings, even if it's an extraordinary one and focuses on the notice/proposals rather than the final voting results (DVA).
2020-12-11 Swedish
MEDIVIR BESLUTAR OM FÖRETRÄDESEMISSION OM CIRKA 170 MSEK OCH ÖVERTILLDELNINGSOPTION MED STARKT STÖD FRÅN BEFINTLIGA OCH NYA SPECIALISTINVESTERARE
Capital/Financing Update Classification · 100% confidence The document is a press release from Medivir AB announcing a rights issue (företrädesemission) of approximately 170 MSEK. It details the terms of the capital raise, including subscription prices, dilution effects, subscription commitments, and the timeline for the extraordinary general meeting. This falls under the category of capital and financing updates as it describes a specific fundraising activity.
2020-12-11 Swedish
MEDIVIR RESOLVES ON A RIGHTS ISSUE OF APPROXIMATELY SEK 170 MILLION AND AN OVER-ALLOTMENT OPTION WITH STRONG SUPPORT FROM EXISTING AND NEW SPECIALIST INVESTORS
Capital/Financing Update Classification · 100% confidence The document is a press release from Medivir AB announcing a rights issue of approximately SEK 170 million and an over-allotment option. It details the terms of the capital raise, subscription prices, dilution effects, and the involvement of specialist investors. This falls under the category of company fundraising and capital structure changes. It is not a prospectus itself, but an announcement of the capital raising event.
2020-12-11 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to September 2020. It contains detailed financial summaries, management commentary (VD har ordet), and operational updates on clinical projects. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2020
2020-11-10 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2020'. It contains comprehensive financial summaries, including income statements, cash flow data, and management commentary for the specified interim period. It is clearly a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. 9M 2020
2020-11-10 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to June 2020. It contains detailed financial summaries (income statements, cash flow, liquidity), management commentary, project portfolio updates, and clinical trial status. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H2 2020
2020-08-20 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.